Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE

Allergy: European Journal of Allergy and Clinical Immunology - Tập 60 Số 3 - Trang 309-316 - 2005
Marc Humbert1, Richard Beasley2, Jon G. Ayres3, Raymond G. Slavin4, Jean‐Louis Hébert5, Jean Bousquet6, Kai-Michael Beeh7, Sância Ramos8, Giorgio Walter Canonica9, S. Hedgecock10, H. Fox10, M. Blogg10, K. Surrey10
1Hôpital Antoine Beclere, Clamart, France
2Medical Research Institute of New Zealand, Wellington, New Zealand
3Liberty Safe Work Research Centre, Aberdeen, Scotland
4Saint Louis University, St. Louis, MO, USA
5CRAAQ, Quebec, Canada
6Hôpital Arnaud de Villeneuve, Montpellier, France
7Johannes-Gutenberg-Universitaet III, Mainz, Germany
8Hospital Central de Asturias, Oviedo, Spain
9Ospedale S. Martino, Genova, Italy
10Novartis Horsham Research Centre, Horsham, West Sussex, UK

Tóm tắt

Background:  Patients with severe persistent asthma who are inadequately controlled despite Global Initiative for Asthma (GINA) 2002 step 4 therapy are a challenging population with significant unmet medical need. We determined the effect of omalizumab on clinically significant asthma exacerbations (requiring systemic corticosteroids) in the first omalizumab study to exclusively enrol patients from this difficult‐to‐treat patient population.Methods:  Following a run‐in phase, patients (12–75 years) inadequately controlled despite therapy with high‐dose inhaled corticosteroids (ICS) and long‐acting β2‐agonists (LABA) with reduced lung function and a recent history of clinically significant exacerbations were randomized to receive omalizumab or placebo for 28 weeks in a double‐blind, parallel‐group, multicentre study.Results:  A total of 419 patients were included in the efficacy analyses. The clinically significant asthma exacerbation rate (primary efficacy variable), adjusted for an observed relevant imbalance in history of clinically significant asthma exacerbations, was 0.68 with omalizumab and 0.91 with placebo (26% reduction) during the 28‐week treatment phase (P =  0.042). Without adjustment, a similar magnitude of effect was seen (19% reduction), but this did not reach statistical significance. Omalizumab significantly reduced severe asthma exacerbation rate (0.24 vs 0.48, P =  0.002) and emergency visit rate (0.24 vs 0.43, P = 0.038). Omalizumab significantly improved asthma‐related quality of life, morning peak expiratory flow and asthma symptom scores. The incidence of adverse events was similar between treatment groups.Conclusions:  In patients with inadequately controlled severe persistent asthma, despite high‐dose ICS and LABA therapy, and often additional therapy, omalizumab significantly reduced the rate of clinically significant asthma exacerbations, severe exacerbations and emergency visits. Omalizumab is effective and should be considered as add‐on therapy for patients with inadequately controlled severe persistent asthma who have a significant unmet need despite best available therapy.

Từ khóa


Tài liệu tham khảo

10.1164/ajrccm.162.6.ats9-00

Global Initiative for Asthma (GINA)., Global strategy for asthma management and prevention

10.3109/02770909809048968

10.1164/ajrccm.157.6.9708092

10.1183/09031936.03.00261903

Davies H, 2000, Methotrexate as a steroid sparing agent for asthma in adults, Cochrane Database Syst Rev, 2

10.1002/14651858.CD001240

10.1002/14651858.CD001240

10.1183/09031936.95.08071091

10.1183/09031936.04.00004904

10.1183/09031936.98.12061322

10.1183/09031936.96.09040636

10.1067/mai.2001.117880

10.1183/09031936.01.00092101

10.1111/j.1365-2222.2004.1916.x

10.1111/j.1398-9995.2004.00533.x

10.1111/j.1398-9995.2004.00550.x

10.1183/09031936.02.00016502

10.1016/S1081-1206(10)62170-9

10.1183/09031936.02.00278102

10.1185/0300799019117010

10.1067/mai.2003.49

10.1378/chest.125.4.1378

10.1136/thx.47.2.76

10.1185/030079903125002171

Committee on Proprietary Medicinal Products., 2003, Notes for guidance on adjustment for baseline covariates

10.1016/S0002-9343(02)01242-1

10.1016/S1081-1206(10)62083-2

Taylor WR, 1992, Impact of childhood asthma on health, Pediatrics, 90, 657, 10.1542/peds.90.5.657

10.1164/ajrccm.149.3.8118625

10.1136/thx.54.11.985

10.1111/j.1467-842X.1999.tb01543.x

Thông tin
Thông tin xuất bản

Allergy: European Journal of Allergy and Clinical Immunology

Tập 60 Số 3

309-316

Thông tin tác giả